Brain metastasis: clinical characteristics, pathological findings and molecular subtyping for therapeutic implications

被引:42
作者
Takei, Hidehiro [1 ]
Rouah, Emilie [2 ]
Ishida, Yusuke [3 ]
机构
[1] Asahikawa Med Univ, Dept Diagnost Pathol, Asahikawa, Hokkaido 0788510, Japan
[2] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA
[3] Hokkaido Univ, Grad Sch Med, Dept Clin Pathol, Sapporo, Hokkaido, Japan
关键词
Brain metastasis; Immunohistochemistry; Differential diagnosis; Unique histologic patterns; Molecular alterations; CENTRAL-NERVOUS-SYSTEM; CELL LUNG-CANCER; CEREBROSPINAL-FLUID CSF; HIPPEL-LINDAU-DISEASE; OF-THE-LITERATURE; BREAST-CANCER; MALIGNANT-MELANOMA; SUBDURAL-HEMATOMA; SOLID TUMORS; LEPTOMENINGEAL METASTASES;
D O I
10.1007/s10014-015-0235-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastases are the most common brain tumors especially in adults. Although they are generally considered a single disease entity which is universally fatal in patients with advanced cancer, brain metastases are remarkably heterogeneous both clinically and pathologically. As members of the multidisciplinary clinical team for the diagnosis and management of metastatic brain tumors, pathologists must be familiar not only with clinicopathologic features of brain metastases but also with any characteristic and clinically significant molecular findings. We discuss here the epidemiology, general gross and microscopic features of brain metastases with emphasis on how to differentiate them from primary brain tumors using immunohistochemistry (e.g., for identification of the primary site and differential diagnosis), and unique pathologic patterns of brain metastases (namely, dural metastasis, leptomeningeal carcinomatosis, miliary metastasis, "intravascular carcinomatosis", and tumor-to-tumor metastasis) with their clinical and radiological characteristics. We specifically address metastatic breast and non-small cell lung cancers which are the two most commonly encountered in daily practice, with emphasis on the molecular alterations related to therapy and their clinicopathologic significance.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 79 条
[1]  
AMER MH, 1978, CANCER-AM CANCER SOC, V42, P660, DOI 10.1002/1097-0142(197808)42:2<660::AID-CNCR2820420237>3.0.CO
[2]  
2-E
[3]  
[Anonymous], TXB RAD ONCOLOGY
[4]  
[Anonymous], CLIN RAD ONCOLOGY
[5]  
[Anonymous], TEMPL REP RES BIOM T
[6]   VISUALIZING HUMAN MALIGNANT MELANOMA AND METASTASES - USE OF CHLOROQUINE ANALOG TAGGED WITH IODINE 125 [J].
BEIERWALTES, WH ;
LIEBERMAN, LM ;
VARMA, VM ;
COUNSELL, RE .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1968, 206 (01) :97-+
[7]   Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer [J].
Berghoff, Anna S. ;
Bago-Horvath, Zsuzsanna ;
Dubsky, Peter ;
Rudas, Margaretha ;
Pluschnig, Ursula ;
Wiltschke, Christoph ;
Gnant, Michael ;
Steger, Guenther G. ;
Zielinski, Christoph C. ;
Bartsch, Rupert .
BREAST JOURNAL, 2013, 19 (02) :149-155
[8]   CSF CYTOLOGY VERSUS IMMUNOCYTOCHEMISTRY IN MENINGEAL CARCINOMATOSIS [J].
BOOGERD, W ;
VROOM, TM ;
VANHEERDE, P ;
DELARIVIERE, GB ;
PETERSE, JL ;
VANDERSANDE, JJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1988, 51 (01) :142-145
[9]   METASTATIC ADENOCARCINOMA OF THE PROSTATE AS A CAUSE OF SUBDURAL-HEMATOMA [J].
BUCCI, MN ;
FARHAT, SM .
JOURNAL OF UROLOGY, 1986, 135 (04) :803-804
[10]   Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].
Camidge, D. Ross ;
Bang, Yung-Jue ;
Kwak, Eunice L. ;
Iafrate, A. John ;
Varella-Garcia, Marileila ;
Fox, Stephen B. ;
Riely, Gregory J. ;
Solomon, Benjamin ;
Ou, Sai-Hong I. ;
Kim, Dong-Wan ;
Salgia, Ravi ;
Fidias, Panagiotis ;
Engelman, Jeffrey A. ;
Gandhi, Leena ;
Jaenne, Pasi A. ;
Costa, Daniel B. ;
Shapiro, Geoffrey I. ;
LoRusso, Patricia ;
Ruffner, Katherine ;
Stephenson, Patricia ;
Tang, Yiyun ;
Wilner, Keith ;
Clark, Jeffrey W. ;
Shaw, Alice T. .
LANCET ONCOLOGY, 2012, 13 (10) :1011-1019